datopotamab,Pembrolizumab,Carboplatin,Cisplatin
Daiichi Sankyo,merck,AstraZeneca
['pembro', 'tropion,lung02', 'datopotamab', 'rux,(-crux),(-trux)', 'sclc', 'lung', 'tropion,lung,02', 'lcsm,(-blcsm)', 'nsclc', 'tropion,lung,2']
 tropion-lung02: datopotamab deruxtecan (dato-dxd) plus pembrolizumab +/- platinum chemotherapy in nsclc. first-line activity: orr 50% and 57% for the doublet and the triplet, respectively. toxic deaths occurring in 5% and 7%, respectively. #asco23 #lcsm 
Medical Oncology 🏥 Hospital General Universitario Gregorio Marañón⎪@myESMO Faculty 🫁 ⎪Power to the patients #endlungcancer #lcsm